MX359634B
(es)
|
2011-12-21 |
2018-10-03 |
Novira Therapeutics Inc |
Agentes antivirales contra la hepatitis b.
|
KR20210081451A
(ko)
|
2012-08-28 |
2021-07-01 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
|
ES2617906T3
(es)
*
|
2012-09-10 |
2017-06-20 |
F. Hoffmann-La Roche Ag |
6-Aminoácido heteroarildihidropirimidinas para el tratamiento y la profilaxis de la infección por virus de la hepatitis B
|
HUE034820T2
(en)
|
2013-02-28 |
2018-02-28 |
Janssen Sciences Ireland Uc |
Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
|
BR112015025052A2
(pt)
|
2013-04-03 |
2021-07-06 |
Janssen Sciences Ireland Uc |
derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
|
AU2014267198A1
(en)
*
|
2013-05-17 |
2015-11-05 |
F. Hoffmann-La Roche Ag |
6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
EA039660B1
(ru)
|
2013-05-17 |
2022-02-24 |
Инсайт Корпорейшн |
Твердая форма производного бипиразола
|
EP2997019B1
(en)
|
2013-05-17 |
2018-08-08 |
Janssen Sciences Ireland UC |
Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
WO2015011281A1
(en)
|
2013-07-25 |
2015-01-29 |
Janssen R&D Ireland |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
US9567299B2
(en)
|
2013-10-23 |
2017-02-14 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
US9498479B2
(en)
|
2013-11-19 |
2016-11-22 |
Sunshine Lake Pharma Co., Ltd. |
Dihydropyrimidine compounds and their application in pharmaceuticals
|
WO2015078393A1
(en)
|
2013-11-27 |
2015-06-04 |
Sunshine Lake Pharma Co., Ltd. |
Processes for preparing dihydropyrimidine derivatives and intermediates thereof
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
KR20160128305A
(ko)
|
2014-02-05 |
2016-11-07 |
노비라 테라퓨틱스, 인코포레이티드 |
Hbv 감염의 치료를 위한 병용 요법
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
CN106061978B
(zh)
|
2014-03-07 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶
|
EP3974426A1
(en)
|
2014-03-13 |
2022-03-30 |
Indiana University Research and Technology Corporation |
Hepatitis b core protein allosteric modulators
|
EP3122747B1
(en)
|
2014-03-28 |
2020-05-20 |
North & South Brother Pharmacy Investment Company Limited |
Dihydropyrimidine compounds and their application in pharmaceuticals
|
AR103222A1
(es)
*
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
CN105859709B
(zh)
|
2015-02-07 |
2018-12-04 |
广东东阳光药业有限公司 |
二氢嘧啶衍生物的复合物及其在药物中的应用
|
CN107108615B
(zh)
|
2015-03-04 |
2020-11-20 |
吉利德科学公司 |
Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物
|
MY190603A
(en)
*
|
2015-03-16 |
2022-04-27 |
Hoffmann La Roche |
Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
|
US10442788B2
(en)
|
2015-04-01 |
2019-10-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
CN106146327B
(zh)
*
|
2015-04-03 |
2019-03-19 |
浙江海正药业股份有限公司 |
一种d-环丝氨酸中间体的合成方法
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
US10301255B2
(en)
|
2015-07-22 |
2019-05-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
TWI721016B
(zh)
|
2015-09-15 |
2021-03-11 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
KR102181168B1
(ko)
*
|
2015-11-03 |
2020-11-23 |
에프. 호프만-라 로슈 아게 |
Hbv 캡시드 조립 억제제와 인터페론의 조합 치료
|
WO2017108630A1
(en)
*
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
WO2017136403A1
(en)
*
|
2016-02-02 |
2017-08-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
AR107633A1
(es)
|
2016-02-19 |
2018-05-16 |
Hoffmann La Roche |
Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
|
SG11201807543YA
(en)
|
2016-03-07 |
2018-09-27 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
MX2018012557A
(es)
|
2016-04-15 |
2019-07-04 |
Janssen Sciences Ireland Uc |
Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
|
JP6957518B2
(ja)
*
|
2016-05-20 |
2021-11-02 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
CN118178444A
(zh)
|
2016-05-27 |
2024-06-14 |
吉利德科学公司 |
使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
|
AU2017277664A1
(en)
|
2016-06-10 |
2019-01-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
CN109689059A
(zh)
|
2016-08-24 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
CN109803967B
(zh)
*
|
2016-09-09 |
2022-05-24 |
浙江海正药业股份有限公司 |
二氢嘧啶类化合物及其制备方法和用途
|
MX2019002678A
(es)
|
2016-09-13 |
2019-05-20 |
Hoffmann La Roche |
Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
|
EP3512845A1
(en)
|
2016-09-15 |
2019-07-24 |
Assembly Biosciences, Inc. |
Hepatitis b core protein modulators
|
BR112019007450A2
(pt)
|
2016-10-14 |
2020-07-07 |
Precision Biosciences, Inc. |
meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
|
US11166954B2
(en)
|
2016-11-18 |
2021-11-09 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Dihydropyrimidine compound and preparation method and use thereof
|
CN109790145B
(zh)
*
|
2016-11-18 |
2020-09-22 |
四川科伦博泰生物医药股份有限公司 |
二氢嘧啶类化合物及其制备方法和用途
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
CA3055194A1
(en)
|
2017-03-02 |
2018-09-07 |
Assembly Biosciences, Inc. |
Cyclic sulfamide compounds and methods of using same
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
JP7260488B2
(ja)
*
|
2017-06-26 |
2023-04-18 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
ジヒドロピリミジン化合物、及び医薬におけるその使用
|
CA3066857A1
(en)
|
2017-06-27 |
2019-01-03 |
Janssen Pharmaceutica Nv |
Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
|
WO2019040102A1
(en)
|
2017-08-22 |
2019-02-28 |
Gilead Sciences, Inc. |
THERAPEUTIC HETEROCYCLIC COMPOUNDS
|
EP3675637A4
(en)
|
2017-08-28 |
2021-05-19 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
CN109678859B
(zh)
|
2017-10-18 |
2020-12-29 |
广东东阳光药业有限公司 |
二氢嘧啶类化合物及其在药物中的应用
|
AR113826A1
(es)
|
2017-11-02 |
2020-06-17 |
Aicuris Gmbh & Co Kg |
Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
|
AU2018361365C1
(en)
|
2017-11-02 |
2021-08-05 |
Aicuris Gmbh & Co. Kg |
Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
|
US10723733B2
(en)
|
2017-12-06 |
2020-07-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
PL3752501T3
(pl)
|
2018-02-13 |
2023-08-21 |
Gilead Sciences, Inc. |
Inhibitory pd-1/pd-l1
|
IL311485A
(en)
|
2018-02-16 |
2024-05-01 |
Incyte Corp |
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
|
US10836769B2
(en)
|
2018-02-26 |
2020-11-17 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
CR20200378A
(es)
|
2018-03-14 |
2021-01-08 |
Janssen Sciences Ireland Unlimited Co |
Régimen posológico del modulador del emsalblaje de la cápside
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
ES2980497T3
(es)
|
2018-03-30 |
2024-10-01 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante inhibidores de JAK
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
EP3781556A1
(en)
|
2018-04-19 |
2021-02-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
US11098027B2
(en)
|
2018-07-06 |
2021-08-24 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
CN112384283B
(zh)
|
2018-07-06 |
2023-08-15 |
吉利德科学公司 |
治疗性的杂环化合物
|
CN108947996B
(zh)
*
|
2018-07-12 |
2022-01-18 |
山东大学 |
二氢嘧啶-磺酰胺类衍生物及其制备方法与应用
|
KR102625712B1
(ko)
|
2018-07-13 |
2024-01-19 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
US11053235B2
(en)
|
2018-08-09 |
2021-07-06 |
Janssen Sciences Ireland Unlimited Company |
Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
|
CA3113235A1
(en)
|
2018-09-21 |
2020-03-26 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
US11560370B1
(en)
|
2018-10-22 |
2023-01-24 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of HBV
|
KR102635333B1
(ko)
|
2018-10-24 |
2024-02-15 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
WO2020087107A1
(en)
|
2018-10-31 |
2020-05-07 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
BR112021008255A2
(pt)
|
2018-10-31 |
2021-08-03 |
Gilead Sciences, Inc. |
compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
|
UY38439A
(es)
|
2018-11-02 |
2020-05-29 |
Aicuris Gmbh & Co Kg |
Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
|
AR117188A1
(es)
|
2018-11-02 |
2021-07-21 |
Aicuris Gmbh & Co Kg |
Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
|
AR117189A1
(es)
|
2018-11-02 |
2021-07-21 |
Aicuris Gmbh & Co Kg |
Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
|
AR116948A1
(es)
|
2018-11-02 |
2021-06-30 |
Aicuris Gmbh & Co Kg |
Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
|
EP3873913A1
(en)
|
2018-11-02 |
2021-09-08 |
AiCuris GmbH & Co. KG |
Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
|
AR116947A1
(es)
|
2018-11-02 |
2021-06-30 |
Aicuris Gmbh & Co Kg |
Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
|
BR112021009854A2
(pt)
|
2018-11-21 |
2021-08-17 |
Enanta Pharmaceuticals, Inc. |
heterociclos funcionalizados como agentes antivirais
|
TW202035412A
(zh)
*
|
2018-12-20 |
2020-10-01 |
比利時商健生藥品公司 |
雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
JP7350872B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
3’3’-環状ジヌクレオチドおよびそのプロドラッグ
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
JP2022525522A
(ja)
|
2019-03-25 |
2022-05-17 |
エフ.ホフマン-ラ ロシュ アーゲー |
Hbvコアタンパク質アロステリック修飾剤の化合物の固体形態
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
CA3138384A1
(en)
|
2019-04-30 |
2020-11-05 |
Aicuris Gmbh & Co. Kg |
Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
|
CA3138385A1
(en)
|
2019-04-30 |
2020-11-05 |
Aicuris Gmbh & Co. Kg |
Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
|
US20220227737A1
(en)
|
2019-04-30 |
2022-07-21 |
Aicuris Gmbh & Co. Kg |
Novel oxalyl piperazines active against the hepatitis b virus (hbv)
|
CU20210088A7
(es)
|
2019-04-30 |
2022-06-06 |
Aicuris Gmbh & Co Kg |
Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
|
TW202108576A
(zh)
|
2019-05-06 |
2021-03-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
用於治療hbv感染或hbv誘發的疾病之醯胺衍生物
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
MA56031A
(fr)
|
2019-05-24 |
2022-04-06 |
Assembly Biosciences Inc |
Compositions pharmaceutiques pour le traitement du vhb
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
CA3142513A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
WO2021018238A1
(en)
*
|
2019-07-31 |
2021-02-04 |
Janssen Sciences Ireland Unlimited Company |
Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
IL290999B1
(en)
|
2019-09-30 |
2024-10-01 |
Gilead Sciences Inc |
HBV vaccines and HBV treatment methods
|
US20230031465A1
(en)
|
2019-12-06 |
2023-02-02 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
CN114867717A
(zh)
*
|
2019-12-20 |
2022-08-05 |
詹森药业有限公司 |
杂芳基二氢嘧啶衍生物和治疗乙型肝炎感染的方法
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
WO2021216660A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
EP4139000A1
(en)
|
2020-04-22 |
2023-03-01 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
WO2021216661A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
CA3180706A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
TW202210471A
(zh)
|
2020-06-02 |
2022-03-16 |
美商英塞特公司 |
製備jak1抑制劑之方法
|
WO2022031894A1
(en)
|
2020-08-07 |
2022-02-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
WO2022052923A1
(zh)
*
|
2020-09-08 |
2022-03-17 |
和博医药有限公司 |
二氢嘧啶类化合物、其应用
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
EP4259131A1
(en)
|
2020-12-08 |
2023-10-18 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of vitiligo
|
CN116888118A
(zh)
|
2021-02-05 |
2023-10-13 |
和博医药有限公司 |
苯基二氢嘧啶类化合物及其应用
|
CN113135921B
(zh)
*
|
2021-04-26 |
2022-06-17 |
山东大学 |
二氢嘧啶-螺环类衍生物及其制备方法与应用
|
CN113512035B
(zh)
*
|
2021-04-26 |
2023-11-24 |
山东大学 |
二氢嘧啶-泊马度胺缀合物及其制备方法与应用
|
TW202348237A
(zh)
|
2021-05-13 |
2023-12-16 |
美商基利科學股份有限公司 |
TLR8調節化合物及抗HBV siRNA療法之組合
|
AU2022297367A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
AU2022298639B2
(en)
|
2021-06-23 |
2024-11-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2023069545A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023069544A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023069547A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
WO2023164179A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164181A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164183A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
WO2023164186A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|